Fepradinol oxalate
Fepradinol oxalate is an orally active nonsteroidal anti-inflammatory agent. Fepradinol oxalate inhibits the increase in vascular permeability induced by histamine, 5-hydroxytryptamine, and bradykinin, reduces exudate volume, prevents leukocyte migration, and suppresses acute inflammation models. Fepradinol oxalate also induces thrombotic vasculopathy with epidermal necrosis, without leukocytoclastic vasculitis; triggers occlusive contact dermatitis presenting as purpuric papulonecrotic lesions, and causes strongly positive patch test reactions. Fepradinol oxalate can be used in research related to occlusive contact dermatitis and acute inflammation.
For research use only. We do not sell to patients.
- CAS No.: 1185076-47-4
- Formula: C14H21NO6
- Molecular Weight:299.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vivo
Fepradinol (25 mg/kg; oral; single administration; 30 minutes before zymosan injection) oxalate inhibited dye exudation by 67.2% in the early phase (30 min) of zymosan-induced rat peritonitis, and reduced exudate volume by 27% and dye exudation by 50% in the late phase (3 h)[2].
Fepradinol (100 mg/kg; oral; single administration; administered immediately after carrageenan injection) oxalate reduced exudate volume by 67.2% and leukocyte migration by 76.4% in a carrageenan-induced rat pleurisy model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male, 5-7 weeks old, 150-200 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose; 30 min prior to mediator injection
-
Result:Inhibited histamine-induced vascular permeability by 81.1%.
Inhibited serotonin-induced vascular permeability by 82.0%.
Inhibited bradykinin-induced vascular permeability by 64.1%.
-
Animal Model:Wistar (male, 150-200 g)[2]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose; immediately after carrageenin injection
-
Result:Reduced pleural exudate volume by 67.2%.
Inhibited leucocyte mobilization by 76.4%.
-
Animal Model:Wistar (male, 150-200 g)[2]
-
Dosage:25 mg/kg
-
Administration:p.o.; single dose; 30 min prior to zymosan injection
-
Result:Inhibited dye extravasation by 67.2% at 30 min after zymosan challenge with no effect on exudate volume.
Reduced exudate volume by 27% at 3 h after zymosan challenge.
Inhibited dye extravasation by 50% at 3 h after zymosan challenge.
Chemical Information
-
CAS No. 1185076-47-4
-
Molecular Weight 299.32
-
Formula C14H21NO6
-
SMILES
O=C(C(O)=O)O.OCC(C)(C)NCC(C1=CC=CC=C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fepradinol oxalate Related Classifications
HY-118854A Related Classifications
Powered by Bioz